Adularia AG (previously Recolony)

At Adularia AG, our technology is rooted in the discovery of a potent immune mechanism, which is based on insights from the symbiotic interplay between gut microbes and the immune system. We have identified a novel therapeutic target for immuno-oncology through the discovery of a mechanism by which bacterial metabolites activate a potent anti-tumor immune reaction. By developing a synthetic small molecule that replicates this naturally occurring mechanism, we are developing a novel immunotherapy with groundbreaking therapeutic potential.

Our target is predominantly expressed in tumor-residing macrophages. Once stimulated, the macrophages release cytokines that activate the cytotoxic T-cells, leading to enhanced tumor infiltration and a potent anti-tumor effect. Therefore, our novel immunotherapy is targeted to the tumor microenvironment, promising fewer side effects and a bigger therapeutic window, and has great potential to increase the target population that can benefit from immunotherapies.